Page last updated: 2024-09-05

erlotinib hydrochloride and elacridar

erlotinib hydrochloride has been researched along with elacridar in 2 studies

Compound Research Comparison

Studies (erlotinib hydrochloride)	Trials (erlotinib hydrochloride)	Recent Studies (post-2010) (erlotinib hydrochloride)	Studies (elacridar)	Trials (elacridar)	Recent Studies (post-2010) (elacridar)
4,353	786	3,033	284	8	119

Protein Interaction Comparison

Protein	Taxonomy	erlotinib hydrochloride (IC50)	elacridar (IC50)
ATP-dependent translocase ABCB1	Homo sapiens (human)		0.4427
Broad substrate specificity ATP-binding cassette transporter ABCG2	Homo sapiens (human)		0.2852

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Elmquist, WF; Mittapalli, RK; Sane, R	1
Auvity, S; Buvat, I; Caillé, F; Gerstenmayer, M; Goutal, S; Larrat, B; Mériaux, S; Tournier, N	1

Other Studies

2 other study(ies) available for erlotinib hydrochloride and elacridar

Article	Year
Development and evaluation of a novel microemulsion formulation of elacridar to improve its bioavailability. Journal of pharmaceutical sciences, 2013, Volume: 102, Issue:4 Topics: Acridines; Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Availability; Biological Transport; Brain; Cell Line; Dasatinib; Dogs; Drug Delivery Systems; Emulsions; Erlotinib Hydrochloride; Humans; Mice; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Solubility; Tetrahydroisoquinolines; Thiazoles	2013
Physical blood-brain barrier disruption induced by focused ultrasound does not overcome the transporter-mediated efflux of erlotinib. Journal of controlled release : official journal of the Controlled Release Society, 2018, 12-28, Volume: 292 Topics: Acridines; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; Biological Transport; Blood-Brain Barrier; Erlotinib Hydrochloride; Male; Positron-Emission Tomography; Protein Kinase Inhibitors; Rats, Wistar; Tetrahydroisoquinolines; Ultrasonic Waves	2018

Article

Year

Development and evaluation of a novel microemulsion formulation of elacridar to improve its bioavailability.

Journal of pharmaceutical sciences, 2013, Volume: 102, Issue:4

Topics: Acridines; Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Availability; Biological Transport; Brain; Cell Line; Dasatinib; Dogs; Drug Delivery Systems; Emulsions; Erlotinib Hydrochloride; Humans; Mice; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Solubility; Tetrahydroisoquinolines; Thiazoles

2013

Physical blood-brain barrier disruption induced by focused ultrasound does not overcome the transporter-mediated efflux of erlotinib.

Journal of controlled release : official journal of the Controlled Release Society, 2018, 12-28, Volume: 292

Topics: Acridines; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; Biological Transport; Blood-Brain Barrier; Erlotinib Hydrochloride; Male; Positron-Emission Tomography; Protein Kinase Inhibitors; Rats, Wistar; Tetrahydroisoquinolines; Ultrasonic Waves

2018